Denmark: A large population-based study published in the British Journal of Dermatology, involving more than 100,000 ...

Low-grade systemic inflammation is an independent risk factor for psoriasis, especially moderate to severe disease, results ...

Assertio Holdings, Inc.’s ASRT share price has surged by 5.21%, which has investors questioning if this is right time to sell ...

The following is a summary of “Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and ...

Using risk assessment and nurse education in the High ED/Admission Risk Therapy (HEART) protocol reduced ED visits by 18% ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients ...

In a USC Keck School of Medicine press release, senior author Susanne Hempel, PhD, said, "The main message is, if your doctor ...

These daily habits may be weakening your immune system without you realizing it Learn which ones silently sabotage your ...

Toxicity was moderate: febrile neutropenia, grade 3 infection, grade 2 neurotoxicity, and decreased LVEF after 23 cycles of trastuzumab were observed in 1 patient each. Conclusion: HER2 ...

Bayer will present new data for NUBEQA® (darolutamide) in prostate cancer at the upcoming American Urological Association (AUA) Annual Meeting taking place in Las Vegas from April 26-29, 2025. These ...